- Home
- VYNE vs IMRN Comparison
VYNE vs IMRN Comparison
Compare VYNE & IMRN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VYNE
- IMRN
- Stock Information
- Founded
- VYNE 2003
- IMRN 1994
- Country
- VYNE United States
- IMRN Australia
- Employees
- VYNE N/A
- IMRN N/A
- Industry
- VYNE Biotechnology: Pharmaceutical Preparations
- IMRN Biotechnology: Pharmaceutical Preparations
- Sector
- VYNE Health Care
- IMRN Health Care
- Exchange
- VYNE Nasdaq
- IMRN Nasdaq
- Market Cap
- VYNE 7.9M
- IMRN 9.2M
- IPO Year
- VYNE 2018
- IMRN N/A
- Fundamental
- Price
- VYNE $0.43
- IMRN N/A
- Analyst Decision
- VYNE Buy
- IMRN
- Analyst Count
- VYNE 2
- IMRN 0
- Target Price
- VYNE $8.00
- IMRN N/A
- AVG Volume (30 Days)
- VYNE 3.1M
- IMRN 73.4K
- Earning Date
- VYNE 11-06-2025
- IMRN 08-29-2025
- Dividend Yield
- VYNE N/A
- IMRN N/A
- EPS Growth
- VYNE N/A
- IMRN N/A
- EPS
- VYNE N/A
- IMRN N/A
- Revenue
- VYNE $476,000.00
- IMRN $4,777,422.00
- Revenue This Year
- VYNE N/A
- IMRN N/A
- Revenue Next Year
- VYNE N/A
- IMRN N/A
- P/E Ratio
- VYNE N/A
- IMRN N/A
- Revenue Growth
- VYNE N/A
- IMRN 48.63
- 52 Week Low
- VYNE $0.28
- IMRN $1.50
- 52 Week High
- VYNE $4.30
- IMRN $2.73
- Technical
- Relative Strength Index (RSI)
- VYNE 60.37
- IMRN 76.46
- Support Level
- VYNE $0.32
- IMRN $1.87
- Resistance Level
- VYNE $0.35
- IMRN $1.95
- Average True Range (ATR)
- VYNE 0.02
- IMRN 0.07
- MACD
- VYNE 0.02
- IMRN 0.03
- Stochastic Oscillator
- VYNE 84.88
- IMRN 89.36
About VYNE VYNE Therapeutics Inc.
VYNE Therapeutics Inc is a biopharmaceutical company focused on developing proprietary, innovative and differentiated therapies for the treatment of immuno-inflammatory conditions. Its advanced product candidate is FMX114, which is being evaluated for the potential treatment of mild-to-moderate AD (atopic dermatitis). The company is also in the pre-clinical stages of developing products containing BET (Bromodomain and Extra-Terminal Domain) inhibitor compounds. Its products include AMZEEQ, ZILXI, and FCD105.
About IMRN Immuron Limited
Immuron Ltd is a commercial and clinical-stage biopharmaceutical company focused on the development and commercialization of a novel class of immunomodulator polyclonal antibodies to treat liver diseases, infectious diseases and other immune-mediated diseases, such as colitis. The company's product, IMM-124E, is a proprietary immunomodulatory agent targeted at GI immune-mediated diseases including fatty liver diseases. The company functions in two segments namely, Research and Development and Hyperimmune products.